

## State of Oklahoma SoonerCare

## Rylaze<sup>™</sup> [Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn] Prior Authorization Form

Member Name:	_ Date of Birth:	Member ID#:	
Drug Information			
□Physician billing (HCPCS code:	)	NDC:)	
Dose: Regimen:	Start Date (	or date of next dose):	
Billing Provider Information			
Provider NPI: Provider Name:			
Provider Phone: Provider Fax:			
Prescriber Information			
Prescriber NPI:	Prescriber Name:		
Prescriber Phone: Pres	criber Fax:	Specialty:	
Criteria			
<ul> <li>Acute Lymphoblastic Leukemia         <ul> <li>A. Will Rylaze<sup>™</sup> be used as a component of multi-agent chemotherapy?</li></ul></li></ul>			
For Continued Authorization:         1. Date of last dose:         2. Does member have any evidence of progressive disease while on Rylaze™? Yes No         3. Has the member experienced adverse drug reactions related to Rylaze™ therapy? Yes No         If yes, please specify adverse reactions:         Prescriber Signature:       Date:			
Prescriber Signature: Date: Date: I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge. Failure to complete this form in full will result in processing delays.			

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:	CONFIDENTIALITY NOTICE
University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit	This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error,
Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4	please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.